Poultry Vaccinology Summit April 28-30, Budapest, Hungary ... · PDF fileND vaccination...
Transcript of Poultry Vaccinology Summit April 28-30, Budapest, Hungary ... · PDF fileND vaccination...
YG - 150429
Vectormune ND
a step towards control of Newcastle Disease
Yannick Gardin1, Vilmos Palya1, John Elattrache1, Marcelo Paniago2, Christophe Cazaban2,
Fernando Lozano2, Pascal Paulet3
1Scientific and Innovation Department, 2Global Veterinary Services Poultry department, 3Poultry Franchise department.
Poultry Vaccinology Summit
April 28-30, Budapest, Hungary
YG - 150429
For the control of Newcastle Disease (ND)
vaccination is a very efficacious tool,
if complementary to:
The parameters of ND vaccination
YG - 150429
For the control of Newcastle Disease (ND)
vaccination is a very efficacious tool,
if complementary to:
The parameters of ND vaccination
Good animal husbandry
Stringent Biosecurity
Effective Sanitary Police
YG - 150429
ND vaccination program
must match the field disease pressure:
The parameters of ND vaccination
YG - 150429
ND vaccination program
must match the field disease pressure:
Low ND is a potential risk
Medium ND is a real risk
High ND is a strong risk
The parameters of ND vaccination
YG - 150429
Reliable vaccination against ND
must take into account:
The parameters of ND vaccination
YG - 150429
Reliable vaccination against ND
must take into account:
Importance of vaccine administration
including flock coverage
Interference with Passive immunity
(Maternally Derived Antibodies or
MDA)
The parameters of ND vaccination
YG - 150429
The critical points regarding
vaccine immunity against ND are:
The parameters of ND vaccination
YG - 150429
The critical points regarding
vaccine immunity against ND are:
Onset of Immunity (OOI)
Level of Immunity (LOI)
Duration of Immunity (DOI)
The parameters of ND vaccination
YG - 150429
As of today, there are 2+1 categories
of vaccines against ND:
ND vaccines
YG - 150429
As of today, there are 2+1 categories
of vaccines against ND:
Live attenuated
Inactivated (killed) adjuvanted
ND vaccines
YG - 150429
As of today, there are 2+1 categories
of vaccines against ND:
Live attenuated
Inactivated (killed) adjuvanted
rHVT-F (Vectormune ND)
ND vaccines
YG - 150429
The classical ND vaccines
Category + -
Live Fast OOI Local (& general Imm.)
Susceptible to MDA Post Vaccination Reactions Short lasting Immunity
Killed Long lasting Immunity Susceptible to MDA
Local reaction General Immunity only
ND vaccines
YG - 150429
Category + -
Live Fast OOI Local (& general Imm.)
Susceptible to MDA Post Vaccination Reactions Short lasting Immunity
Killed Long lasting Immunity Susceptible to MDA
Local reaction General Immunity only
ND vaccines
The classical ND vaccines
YG - 150429
The problem of interference with MDA
YG - 150429 (after P.H. Russel, 1993)
27 34 41
Age (days)
serum
tears
Antibody titre*
(10 log)
<1
1
2
3
4
5
1 13 21
*ImmunoPeroxydase Monolayer Assay
6
The problem of interference with MDA
YG - 150429
Live attenuated ND vaccines
The problem of interference with MDA
YG - 150429
Live attenuated ND vaccines
The problem of interference with MDA
% protection / challenge
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
Chickens
Control
MDA
with without
Age (days)
(after Bennejean G. et al., 1978)
YG - 150429
Live attenuated ND vaccines
The problem of interference with MDA
% protection / challenge
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
Chickens
Vaccinated
Control
MDA
with without
Age (days)
(after Bennejean G. et al., 1978)
YG - 150429
Live attenuated ND vaccines
The problem of interference with MDA
Chickens
Vaccinated
Control
MDA
with without
% protection / challenge
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30
Age (days)
(after Bennejean G. et al., 1978)
YG - 150429
Killed (inactivated) ND vaccines
The problem of interference with MDA
YG - 150429
Killed (inactivated) ND vaccines
The problem of interference with MDA
(after Bennejean G. et al., 1978)
0
20
40
60
80
100
120
0 5 10 15 20 30 40 50 60
Age at challenge (days)
% o
f pro
tect
ion
Killed vaccine - No MDA
Killed vaccine - MDA
YG - 150429
rHVT-F (Vectormune ND) vaccine
The problem of interference with MDA
YG - 150429 (Extract from study SCI 193-2012 – SSIU Ceva Phylaxia)
La Sota (Phylaxia)
antigen
rHVT-F (Vectormune ND) vaccine
The problem of interference with MDA
YG - 150429 (Extract from study SCI 193-2012 – SSIU Ceva Phylaxia)
La Sota (Phylaxia)
antigen
rHVT-F (Vectormune ND) vaccine
The problem of interference with MDA
YG - 150429 (Extract from study SCI 193-2012 – SSIU Ceva Phylaxia)
La Sota (Phylaxia)
antigen
rHVT-F (Vectormune ND) vaccine
The problem of interference with MDA
YG - 150429 (Extract from study SCI 193-2012 – SSIU Ceva Phylaxia)
La Sota (Phylaxia)
antigen
rHVT-F (Vectormune ND) vaccine
The problem of interference with MDA
YG - 150429
Efficacy of Vectormune ND
YG - 150429
Laboratory trials in Thailand (vvNDV)
Efficacy of Vectormune ND
YG - 150429
Laboratory trials in Thailand (vvNDV)
Efficacy of Vectormune ND
VECTORMUNE HVT-NDV
Laboratory challenge trials in Thailand
0
20
40
60
80
100
120
14 21 28
Age at challenge (days)
Per
cent
age
of p
rote
ctio
n
Vectormune HVT-NDV
Cevac Vitapest L
Cevac Vitapest L + Vectormune HVT-NDV
Cevac Vitapest L + Cevac Broiler ND K
Controls
YG - 150429
Efficacy of Vectormune ND
Laboratory trials at SSIU Ceva Phylaxia
YG - 150429
- Commercial broilers (20 per group)
- Vectormune ND SQ or in-ovo (-3d)
- Challenge :
- 105 EID50 Chimalhuacan NDV strain
- at 3 or 4 or 6 weeks of age
- IN + ON route
- Oropharyngeal and Cloacal swabs taken 3 and 7 days PC
- Virus quantification using RT-PCR
Efficacy of Vectormune ND
Laboratory trials at SSIU Ceva Phylaxia
YG - 150429 33
Clinical protection
Efficacy of Vectormune ND
YG - 150429
* * * * * * * *
Challenge at D28
Reduction
of
shedding
Efficacy of Vectormune ND
YG - 150429
* * * * * * * *
Reduction
of
shedding
Efficacy of Vectormune ND
Challenge at D28
YG - 150429 36
Does it protect
against
various types
of NDV ?
F
insert
Efficacy of Vectormune ND
YG - 150429 37
F
insert Yes !
Does it protect
against
various types
of NDV ?
Efficacy of Vectormune ND
YG - 150429 38
F
insert Yes !
Yes !
Does it protect
against
various types
of NDV ?
Efficacy of Vectormune ND
YG - 150429 39
F
insert Yes !
Yes !
Yes !
Does it protect
against
various types
of NDV ?
Efficacy of Vectormune ND
YG - 150429 40
F
insert Yes !
Yes !
Yes !
Yes !
Does it protect
against
various types
of NDV ?
Efficacy of Vectormune ND
YG - 150429
- Lohman Brown layer pullets with MDA
- Vectormune ND (d1 – SQ)
- Vectormune ND (d1 – SQ) + Cevac Vitapest L (ED)
+ Cevac ND IB EDS K (w15 – IM)
- Challenge :
- 105 EID50 Malaysian 2010 vvNDV viscerotropic
isolate (Genotype VII) - IN route (0,1 ml)
- at 3, 4, 6, 10, 33, and 72 weeks of age
Efficacy of Vectormune ND
Controlled trials at SSIU Ceva Phylaxia
YG - 150429
Protection of layers against vvNDV challenge
0
20
40
60
80
100
120
3 4 6 10 15 33
Age at challenge (in weeks)
% P
rote
ctio
n
Vectormune HVT-NDV
Vectormune HVT-NDV +
Cevac Vitapest L + KilledControls
33 72
Efficacy of Vectormune ND
Controlled trials at SSIU Ceva Phylaxia
YG - 150429
Vectormune ND: vaccination programs
Disease pressure
MDA Vectormune ND Live ND Priming
D1
Live ND boost
D14-18
Low O O
Medium O O O
High O O O O
YG - 150429
Conclusions: Vectormune ND
Vaccine « take » is not prevented by MDA
Vaccine take depends only on the quality of
administration
Administration can be done at the hatchery
(in-ovo or SQ) i.e. in the most reliable way
Early immunity can be re-inforced by MDA
and live vaccine(s) if necessary
Duration of immunity is outstanding
Shedding of challenge virus is reduced
YG - 150429
Conclusions: Vectormune ND
A (major) step towards
a better control of
Newcastle Disease
YG - 150429
THANK YOU
FOR YOUR ATTENTION